{"id":250711,"date":"2025-12-18T00:00:00","date_gmt":"2025-12-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/dlsfon0014-2022-biopharma-pancreatic-cancer-landscape-forecast-disease\/"},"modified":"2026-03-31T10:23:57","modified_gmt":"2026-03-31T10:23:57","slug":"dlsfon0014-2025-biopharma-pancreatic-cancer-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0014-2025-biopharma-pancreatic-cancer-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Pancreatic Cancer &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast"},"content":{"rendered":"<p>Pancreatic cancer remains difficult to treat owing to the lack of treatment options\u2014primarily surgery, radiation, and chemotherapy. Pancreatic adenocarcinoma represents the vast majority of pancreatic cancer, whereas pancreatic neuroendocrine tumors (<abbr data-abbreviation-entity=\"7729\" title=\"pancreatic neuroendocrine tumor\">PNET<\/abbr>s) comprise only a small subset. First-line treatment for advanced or metastatic pancreatic adenocarcinoma relies on <abbr data-abbreviation-entity=\"6698\" title=\"5-fluorouracil + leucovorin + irinotecan + oxaliplatin\">FOLFIRINOX<\/abbr> or gemcitabine plus nanoparticle paclitaxel, while synthetic somatostatin analogues remain the cornerstone for <abbr data-abbreviation-entity=\"7729\" title=\"pancreatic neuroendocrine tumor\">PNET<\/abbr> management. Second-line pancreatic adenocarcinoma treatment options include liposomal irinotecan plus <abbr data-abbreviation-entity=\"5258\" title=\"5-fluorouracil\">5-FU<\/abbr> with leucovorin for patients who failed gemcitabine-based therapy; Merus\u2019s zenocutuzumab is an option for previously treated patients with <abbr data-abbreviation-entity=\"8531\" title=\"neuregulin 1\">NRG1<\/abbr> fusion-positive pancreatic adenocarcinoma, and AstraZeneca \/ Merck\u2019s olaparib is approved as a maintenance therapy in germline <abbr data-abbreviation-entity=\"7699\" title=\"breast cancer gene\">BRCA<\/abbr>-mutated cases. Despite these advancements, survival benefits remain modest, highlighting the urgent need for novel therapies. Late-phase targeted treatments such as <abbr data-abbreviation-entity=\"6567\" title=\"rat sarcoma\">RAS<\/abbr> inhibitors, <abbr data-abbreviation-entity=\"5337\" title=\"mitogen-activated protein kinase kinase\">MEK<\/abbr> inhibitors, and radiotherapeutics will provide better treatment options.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>How large are the clinically and commercially relevant pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumor (<abbr data-abbreviation-entity=\"7729\" title=\"pancreatic neuroendocrine tumor\">PNET<\/abbr>) drug-treatable populations, and how will drug-treatment rates change over the 2024-2034 forecast period?<\/li>\n<li>What is the current treatment algorithm for pancreatic adenocarcinoma and <abbr data-abbreviation-entity=\"7729\" title=\"pancreatic neuroendocrine tumor\">PNET<\/abbr>s in the major markets? What are interviewed experts\u2019 views on current therapies?<\/li>\n<li>Which are the most promising emerging therapies in the late-phase pipeline? What uptake and patient shares can late-phase pipeline agents in development for pancreatic cancer expect to secure?<\/li>\n<li>What are the key drivers and constraints in pancreatic cancer, and how will this market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Geography:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><strong>Primary research:<\/strong> Country-specific interviews with thought-leading medical oncologists. Survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology:<\/strong> Diagnosed incidence by country and disease stage; clinically and market-relevant drug-treatable populations<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key pancreatic cancer therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies<\/p>\n<p><b>Product description<\/b><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW200847613 BCX0 round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-250711","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-pancreatic-cancer","biopharma-therapy-areas-solid-tumors","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250711\/revisions"}],"predecessor-version":[{"id":575250,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250711\/revisions\/575250"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}